We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research compound — not a dietary supplement
RAD-140 (Testolone) is a research compound, not a regulated dietary supplement. It is sold for research or off-label use. The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most RAD-140 (Testolone) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2011–2024 with a typical study size of 22 participants.
Based on 6 studies · 22 total participants
Confidence
LowBy outcome
RAD-140 (Testolone) has an evidence score of 3.2/10 — emerging evidence based on 6 indexed studies. An unapproved selective androgen receptor modulator (SARM) sold grey-market for muscle and body composition. Its anabolic and anti-cancer data are preclinical (cells/animals); the only human studies are a Phase-1 breast-cancer safety trial and case reports of severe liver injury. WADA-banned, suppresses natural testosterone, and grey-market products are routinely mislabeled. Representative study: PMID 34565686.
The commonly studied dose of RAD-140 (Testolone) is No legitimate dosing exists — RAD-140 is an unapproved research chemical, not a supplement or medicine. Grey-market protocols cite ~10 mg/day, but products are frequently mislabeled and this is not a recommendation.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Ostarine (MK-2866 / Enobosarm)
Mostly mechanism / observationalA non-steroidal SARM (enobosarm / MK-2866) developed for muscle wasting and cancer cachexia. Real, large randomized trials show it genuinely adds lean body mass — but it has NEVER been approved: the pivotal cancer-cachexia program met its lean-mass endpoints while missing physical-function endpoints, so a durable functional benefit is unproven. Sold widely as a grey-market 'body-recomp' research chemical, it carries documented drug-induced liver injury, HDL/lipid suppression, and testosterone (HPTA) suppression, is banned by WADA, and the products sold online are frequently mislabelled. Real anabolic signal, unproven function, real harms.
Notable regimens that report including RAD-140 (Testolone) — documented, not endorsed.
Last reviewed June 2026 · evidence from 6 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
RAD-140 (Testolone) — selective androgen receptor modulator (SARM)
An unapproved selective androgen receptor modulator (SARM) sold grey-market for muscle and body composition. Its anabolic and anti-cancer data are preclinical (cells/animals); the only human studies are a Phase-1 breast-cancer safety trial and case reports of severe liver injury. WADA-banned, suppresses natural testosterone, and grey-market products are routinely mislabeled.
RAD-140's anabolic and anti-cancer data are entirely preclinical (cells/animals) — there are NO human efficacy trials for muscle or strength. The only human evidence is a Phase-1 breast-cancer safety trial (in which liver enzymes commonly rose) and multiple case reports of severe drug-induced liver injury. It suppresses natural testosterone, is WADA-banned, and grey-market products are routinely mislabeled. The score reflects a documented human harm signal with no proven human benefit.
RAD-140 (testolone) is a nonsteroidal selective androgen receptor modulator (SARM) discovered as a drug candidate to activate the androgen receptor in muscle and bone while sparing the prostate.
It was originally developed for muscle-wasting conditions and later studied as an androgen--targeted agent in androgen/estrogen-receptor-positive breast cancer.
It is NOT an approved drug or a dietary supplement anywhere — it is a research chemical that has become popular on the grey market for body composition and 'recomp.' The honest evidence picture is narrow and unflattering: the muscle/anabolic and anti-cancer findings are preclinical (cell-line, xenograft, and animal models, led by the 2011 discovery paper from Radius Health); there are NO human efficacy trials for muscle or strength.
The single substantial human study is a first-in-human Phase-1 dose-escalation in metastatic breast cancer, which was a safety/PK study (not an efficacy RCT) and in which liver-enzyme elevations were among the most common adverse events.
Outside that trial, the human literature is dominated by case reports of severe drug-induced liver injury (cholestatic hepatitis, jaundice) in young men taking RAD-140 for bodybuilding.
Like all androgen-receptor agonists it suppresses the hypothalamic-pituitary-gonadal axis (lowering natural testosterone), and it is prohibited at all times by WADA.
Chemical analyses of products sold online show frequent mislabeling — the stated SARM is often missing, substituted, under- or over-dosed, or spiked with other undeclared drugs. The score is low: no human efficacy evidence, documented serious human harm, regulatory prohibition, and an unreliable grey-market supply.
Binds the androgen receptor with high affinity and activates it preferentially in muscle and bone while sparing the prostate (tissue-selective in preclinical models).
AR activation drives anabolic gene programs in muscle and bone in animal/in-vitro models — the basis of its body-composition use, unproven in humans.
Like other androgen-receptor agonists, it suppresses the hypothalamic-pituitary-gonadal axis, lowering endogenous testosterone.
How RAD-140 (Testolone) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
No legitimate dosing exists — RAD-140 is an unapproved research chemical, not a supplement or medicine. Grey-market protocols cite ~10 mg/day, but products are frequently mislabeled and this is not a recommendation.
Can be taken without food
| Form | Type |
|---|---|
| 💊None — unapproved research chemical | Recommended |
Grey-market products are frequently mislabeled or adulterated; quality and contents cannot be assumed from the label.
Minimum: 8 weeks
Optimal: 12 weeks
Cycling: Not required
Note: No validated regimen; not an approved supplement or medicine.
Dose-response data unavailable. The current published research for RAD-140 (Testolone) does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Promoted for muscle gain and 'recomp'; the anabolic evidence is from animal and in-vitro models, with no human efficacy trials.
Inhibited AR/ER+ breast-cancer growth in cell and xenograft models; a first-in-human Phase-1 trial showed only preliminary target engagement, not established efficacy.
Multiple human case reports of severe cholestatic liver injury (jaundice, markedly elevated enzymes) after use for bodybuilding; liver-enzyme rises were common in the Phase-1 trial.
Suppresses the natural HPTA axis, lowering endogenous testosterone; recovery and post-cycle effects are not characterized in trials.
Avoid — unapproved research chemical with a documented serious-harm signal and no proven human benefit.
Prohibited at all times by WADA; a positive test results from any use.
Especially dangerous — RAD-140 causes drug-induced liver injury.
Additive risk of drug-induced liver injury, which is already documented with RAD-140 alone.
Additive androgenic load and HPTA suppression; combined hepatic and hormonal risk.
Tip: Multiple case reports after bodybuilding use; stop immediately and seek care for jaundice, dark urine, or right-upper-quadrant pain. No safe dose established.
Tip: Among the most common adverse events in the Phase-1 trial; monitor liver function — though no use is recommended.
Tip: HPTA suppression is expected with androgen-receptor agonists; recovery is not characterized in trials.
The best time to take RAD-140 (Testolone) is in the morning. It can be taken on an empty stomach. There is no validated human dosing.
RAD-140 (Testolone) should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are drug-induced liver injury (cholestatic hepatitis, jaundice), elevated liver enzymes (AST/ALT), testosterone suppression (low libido, fatigue, mood changes). Use caution if any of these apply to you: Anyone — unapproved research chemical with documented severe liver injury; Liver disease or elevated liver enzymes; Athletes subject to anti-doping (prohibited at all times by WADA).
LGD-4033 (Ligandrol)
Mostly mechanism / observationalA nonsteroidal SARM with one small Phase-1 human RCT that did show dose-dependent lean-mass gain over 21 days — but at the cost of suppressed testosterone and HDL cholesterol even at low doses. It was never approved as a medicine, multiple case reports tie it to cholestatic liver injury, internet 'SARM' products are routinely mislabelled, and it is banned by the World Anti-Doping Agency. Sold only as an unregulated grey-market research chemical for body composition.